= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Letertre

MSACL 2018 EU Abstract

Topic: Metabolomics

Podium Presentation in the Ether on Thursday at 11:00 (Chair: Nicola Gray)

Analytical Strategies to Study the Interaction Between Microbiota and Drug Metabolism Using Targeted and Untargeted LC-MS-based Metabolomics

Marine Letertre (Presenter)
Imperial College London

Presenter Bio(s): I am currently a second year PhD student at Imperial College London, studying the interactions between gut microbiota and drug metabolism. I am mainly using targeted and untargeted LCMS as well as NMR metabolic profiling and amplicon sequencing. I have graduated in 2015 from the University of Nantes (France), with a Master’s Degree (Hons), specialized in the use of Natural Active Ingredients for a pharmaceutical application. Although I am a chemist by training, I have always worked at the interface of Chemistry and Biology, allowing me to take part on diverse projects such as understanding the toxicity of Bisphenol A on human testicular explants by MALDI-Imaging Mass Spectrometry (Rennes, France) or developing a novel class of irreversible kinase inhibitors using organic chemistry technics as well as enzyme assays and molecular modelling (Auckland, New Zealand).

Authors: Marine Letertre (1), Nyasha C. Munjoma (2), Lesley Hoyles (1), Aadra Bhatt (3), Anne L. McCartney (4), Muireann Coen (5), Matthew Redinbo (3), Jeremy K. Nicholson (1), Jonathan R. Swann (1), & Ian D. Wilson (1)
(1) Imperial College London, London, UK. (2) Waters Corporation, Wilmslow, UK. (3) University of North Carolina, Chapel Hill, USA. (4) The University of Reading, Reading, UK. (5) AstraZeneca, Cambridge, UK.

Abstract

Metabonomics, and particularly pharmacometabonomics, is a useful tool for patient stratification and to establish individualized drug therapy and limited ADRs to improve patient journey. We have used the pharmacometabonomics principle on animal experiments to study the interaction between the microbiome and several drugs. The general workflow applied both untargeted LC-MS for endogenous metabolic phenotyping and a targeted approach to quantify the drug of interest and its metabolites, in complement of NMR and amplicon sequencing. It enabled the impact of drugs on the gut microbiota community structure to be investigated as well as the influence of the microbiome on the metabolism of these drugs and their metabolites.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no